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Mucous membrane pemphigoid (MMP), previously known as "cicatricial pemphigoid", refers to a 84 heterogenous group of autoimmune subepidermal blistering disorders that affect mucous membranes at 85 the orifices, including the ocular, oral, nasopharyngeal, tracheal, oesophageal, anogenital and 86 genitourinary; the skin may or may not be affected. 1 Inflammation is associated with progressive 87 cicatrisation (scarring) at all sites, with the exception of the oral mucosa, where scarring is uncommon. 88
The reported incidence of MMP is approximately 1.16 to 2.0 per million population 2,3 and prevalence 89 1:40,000. 4 Approximately 70% of patients with MMP have ocular involvement (ocular MMP). 5,6 90 Ocular MMP, characterised by relapsing conjunctivitis with progressive conjunctival cicatrisation, is 91 the commonest cause of cicatrising conjunctivitis in the United Kingdom with an incidence of 0.8 per 92 million population. 7 Although the mean age of onset of ocular MMP is 65 years, 8, 9 it also occurs in 93 children and young adults in whom the disease is more aggressive. [10] [11] [12] The current standard of care for 94 patients with symptomatic ocular MMP is systemic immunomodulatory therapy, because of the failure 95 of topical therapies in MMP affecting this site. 11, [13] [14] [15] However, the response to systemic 96 immunomodulatory therapy is variable, and side effects are common. 8, 16 Chronic discomfort is normal, 97 and 20% of cases become bilaterally blind due to ocular surface failure, corneal vascularisation, and 98 corneal opacification. 16,17 99 100 Early diagnosis and treatment are essential to reduce sight-threatening complications in ocular MMP. It 101 is recommended that a clinical diagnosis of MMP is made only when the clinical criteria for MMP at 102 any site are accompanied by laboratory evidence of an antibody mediated disease at the epithelial 103 basement membrane. 1 The latter requires a biopsy from any mucosal site (not necessarily ocular), or 104 from skin, demonstrating linear deposition of IgG and/or IgA and/or complement at the epithelial 105 basement membrane (BM) using a direct immunofluorescence (DIF) technique. 1,18-20 106 107 Ocular MMP limited to the eye (ocular only MMP) has varied from 14/74 (19%) to 26/86 (30%) 108 depending on the definition in one study 9 and 18/50 (36%) in another. 7 However, it is recognised that 109 in ocular only MMP, half of the patients with conjunctival disease typical of MMP, have had 110 intermittent or repeatedly negative DIF. 9, 15, [21] [22] [23] [24] were recorded as positive or negative. If DIF had not been carried out previously, biopsies from 144 affected mucosa or skin were taken and processed for DIF using standard techniques. 26 We were 145 unable to standardize the DIF method because many patients had been referred with DIF results from 146 biopsies that had performed locally. Details of the DIF findings were not available for all the patients 147 and were not recorded. For this study, the diagnosis of ocular MMP was based on clinical findings 148 typical of ocular MMP (after exclusion of other causes of scarring conjunctivitis), 8,15 regardless of DIF 149
results. 150
Data collection used a case report form designed for this study (Supplementary Appendix 1, 151 online). A clinical history was taken from all patients, focusing on their general health and the 152 involvement of other anatomical sites by MMP. Other information obtained included demographic 153 details, a medical history of autoimmune diseases or malignancy, and the ophthalmic history. 154
All patients then underwent a detailed clinical assessment by a multi-disciplinary team of 155 ophthalmologists, otolaryngologists and a dermatology and oral medicine specialist. All anatomical 156 sites that can potentially be affected by MMP, apart from the oesophagus (and larynx in a subset of 157 patients), were screened for signs of disease. Fourteen patients declined nasopharyngeal and anogenital 158 examination. When a patient declined screening of particular anatomical sites (apart from the eye), site 159 involvement was determined from the disease history. History is necessary because for most oral 160 disease cases, and some with nasopharyngeal involvement, there is no residual scarring to indicate a 161 disease episode in patients in remission. Table 1a summarises the sites assessed for involvement by MMP and the positive screening criteria for each site. Table 1b describes the classification used MMP 163 involvement of sites using both screening and history. 164
Ophthalmological Assessment 165
During ophthalmological assessment, the best corrected visual acuity for each eye was recorded in 166
Snellen's notation. A score was given to each eye according to its visual acuity: 1=6/7.5 or better, 167 2=6/9-6/12, 3=6/18-6/36, 4=6/60 or worse, 5=3/60-count fingers, 6=hand movements, 7=perception of 168 light, and 8=no perception of light. For each patient, the score from the eye with the worst visual acuity 169 was used for analysis. 170
Each eye was given an inflammation scoring methodology in the case report form 171
(Supplementary Appendix 1 online). The score for each quadrant of bulbar conjunctiva ranged from 0-172 4 giving a maximum score of 16 for each eye, and of 32 for both eyes. A patient was defined as having 173 significant ocular inflammation if the total score was 5 or more: minimal levels of conjunctival 174 inflammation may be due to blepharoconjunctivitis or dry eye rather than to underlying MMP related 175
inflammation. 176
Tauber staging was used to assess the extent of conjunctival scarring. 27 All patients had 177 conjunctival scarring by definition. Severe scarring was defined as Tauber stage greater than IIb (lower 178 fornix shortening more than 25%) or Tauber stage greater than IIIb (presence of lower lid 179 symblepharon more than 25%). 180
Amongst the other indices of severity assessed were corneal pathologies expected to reduce 181 vision: vascularisation, scarring, ulceration, and conjunctivalisation. Severe disease was classified as 182 any of these involving the central 5mm of cornea (pupillary zone). 183 Ocular discomfort as reported by patients were graded as: none, tolerable, moderate, or severe. 184
The extent to which vision affects daily activities as reported by patients were graded as: unaffected, 185 adequate for needs, and restricts activity. 186
Statistical analysis 187
Data were managed in Excel (Microsoft) and analysed using Statistical Program for Social Sciences 188 (SPSS©) Version 22 (2013 IBM© US). Differences in the distribution of categorical variables between 189 groups were analysed using the Chi-squared test. Fisher's exact test was used when expected 190 frequencies of cells less than 5 were present. For continuous variables, differences in distributions 191 between DIF positive and DIF negative groups were analysed using the Mann-Whitney U test. Differences between patients grouped by differences in involvement at different sites 205 Table 3 describes the sites involved in this group of ocular MMP patients and compares their 206 demographic characteristics, the numbers using systemic immunotherapy at the time of screening, 207 those who had asymptomatic disease identified at screening, and the DIF results. Asymptomatic 208 disease at different sites was common and identified in 8/19 (42.1%) patients with ocular and oral 209 disease and 6/10 (60.0%) patients with ocular, oral and nasopharyngeal disease. Of those with evidence 210 of mucosal involvement in the nasopharynx, 6/10 (60%) were asymptomatic. Compared to patients in 211 other groups, patients who had ocular only involvement were more likely to have a negative DIF status 212 (p=0.03). Figure 1 in various other combinations. The anatomical sites involved were classified using the criteria 216 described in Table 1 . 217
218
Severity of disease comparison in DIF positive versus DIF negative ocular MMP patients 219 Table 4 and Figure 2 compare the severity of disease in having positive and negative DIF results. For 220 all cases of ocular disease there was a trend to more severe disease in DIF negative patients, with 221 differences that were statistically significant for the presence of central corneal disease. 222
For the 19 patients with ocular only MMP, disease severity indices (Table 4) were evenly 223 balanced with trends to less conjunctival scarring in the DIF negative group but worse corneal disease, 224 and a very similar requirement for systemic immunotherapy. 225
Visual acuity scores were statistically significantly worse in DIF negative patients (p=0.03). 226
However, due to clinically significant ocular co-morbidities in these patients, visual acuity scores can 227 be difficult to interpret. There was no statistically significant difference in the proportion of patients 228 who reported restriction of daily activities due to poor vision (p=0.258). Reported ocular discomfort 229 scores were similar in both DIF positive and DIF negative patients (p=0.104). This study of patients having ocular MMP were also assessed for the presence of MMP at extraocular 235 sites. Limitations of this study are the inclusion of patients who declined screening and examination of 236 particular anatomical sites, such as nasopharyngeal and anogenital regions, for whom the assumption 237 was made that these sites were uninvolved in the absence of a history for MMP at that site. Although 238 the clinical signs and scarring parameters in the case report form used in this study were based on 239 previously published systems, 27 these are not validated. There is currently no validated scheme for 240 measuring the severity and activity of disease in scarring conjunctivitis. In addition, this was a cross sectional study so that, although we could record the requirement for systemic immunosuppressive 242 therapy at the time of the study, we could not assess the effect of treatment on outcomes. However, in 243 our previous study the datasheet evaluating long term outcomes is included in the supplementary 244 data. 16 We have used this to assess the effect of the first treatment episode in DIF positive and negative 245 ocular MMP patients respectively: these data are shown in Supplementary Figure 1 which show no 246 major differences in the outcomes. Immunosuppressive treatments were administered according to 247 previously published step-wise regimen. 15 248
We have shown that a substantial proportion of cases had ocular only disease (20/73 249 [27.39%]) without involvement of other sites: similar to that in previous reports. 7, 9, 17 We also 250 confirmed that in this subset with ocular only disease, 11/19 (55%) were significantly less likely 251 (p=0.03) to have a positive DIF result. This proportion is similar to what has been previously described 252 for this group of patients. 9,15,21-24 Twenty six patients (35.6%) of the overall ocular MMP cohort were 253 DIF negative. This is the first prospective study to provide a detailed analysis of clinical differences 254 between patients, meeting clinical criteria of ocular MMP, irrespective of their DIF findings. This has 255
shown that there are few differences between the DIF negative and DIF positive subsets, with two 256 parameters, central corneal pathology and prior lid or conjunctival surgery, being significantly more 257 common in the DIF negative group. This evidence provides no support for the classification of DIF 258 negative MMP as a different disease from DIF positive MMP as has been suggested 1 and is in keeping 259 with findings in two other studies exploring the issue of DIF negative ocular MMP patients 23, 24 . 260 This is also the first study, to our knowledge, that has reported the results of screening of 261 asymptomatic sites in MMP patients. Asymptomatic ocular, oral and nasopharyngeal disease were 262 frequently identified. This finding is clinically significant as some ocular MMP patients develop 263 progressive cicatrisation without clinical inflammation, 28 discomfort from MMP may be accepted as a 264 matter of course by patients having oral MMP who can be expected to benefit from appropriate 265 management. Lastly, asymptomatic tracheal involvement has been reported in a series of patients with 266 nasopharyngeal disease 29 and can lead to severe complications which may benefit from early 267
identification. 268
Our demonstration that, in patients meeting clinical criteria for ocular MMP the direct 269 immunofluorescence findings do not relate to the clinical phenotype, supports our previous 270 recommendation that clinical criteria, together with the result of conjunctival biopsies for both routine 271 histopathology and DIF, can be used to make a definitive diagnosis of DIF negative ocular MMP. This 272 is justified because the more than 20 other diseases causing conjunctival scarring can be excluded with 273 a combination of these biopsy results and clinical criteria. Histopathology is needed to exclude ocular 274 surface tumors whereas DIF is used not only to confirm a diagnosis of MMP, but also to distinguish 275 MMP from other causes of conjunctival scarring; these include lichen planus, showing shaggy 276 discontinuous fibrinogen deposits at the BMZ, 30-32 and pemphigus having intraepithelial antibodies. 1 277
The infrequent cases of inflammation and progressive scarring, associated with both Stevens Johnson 278 syndrome and topical medications (following withdrawal of the medication) that are DIF negative 279 should also be treated in the same way as DIF negative MMP. If DIF is negative then alternative 280 evidence of autoantibodies to epithelial BM proteins may be available from autoantibody detection, using indirect immunofluorescence, ELISA or Western blotting. However these tests are often negative, 282 and therefore not required for diagnosis using the Consensus criteria; 1 in our experience they are also 283 usually negative in DIF negative patients. Diagnostic criteria for the many causes of cicatrising 284 conjunctivitis, and a flow chart for this, have been described in detail in a recent review. 15 285
Whereas we agree that in ocular only DIF a conjunctival biopsy should be taken for DIF 286 testing, and that for some purposes, such as the investigation of some aspects of the 287 immunopathogenesis of conjunctival MMP, tissue should only be used from patients having at least 288 one positive DIF result [33] [34] [35] , we hope that the diagnosis of DIF negative ocular MMP will be widely 289 accepted for clinical management purposes. This will allow patients with this condition to access 290 appropriate therapy without the delays that are currently common, because of failure to meet the 291 existing diagnostic criteria for MMP affecting other sites. 292
Moreover, performing immunofluorescence on small conjunctival samples can be operator-293 dependent and the interpretation of immunofluorescence results subjective. Thus, technical and 294 interpretation factors may contribute to both false negative and false positive DIF findings. 295
Furthermore, the absence of identifiable autoantibodies in some patients with clinical MMP may not 296 only be due to undetectably low levels of antibody but also suggests the possibility that a subset of 297 MMP patients have disease that results from a cell mediated response resulting from autoreactive T 298 cells to epithelial basement membrane proteins, without circulating antibodies. This would parallel the 299 situation in most other autoimmune diseases which result from variable levels of cellular and 300 autoantibody driven responses. 15 We think that this hypothesis deserves further investigation in MMP. 301 DIF unknown 4 (5.5%) 1 (5.0%) 0 (0.0%) 0 (0.0%) 3 (12.5%) DIF + = Direct immunofluorescene positive; DIF -= Direct immunofluorescence negative; * Sites involved detected at the time of this cross-sectional study; some sites may be in remission; † Oral, nasopharyngeal, skin, anogenital involvement in various combinations; ‡ 5 were DIF +; § 3 were DIF + and 1 was DIF -; II 2 were DIF -; ** 4 were DIF + and 2 were DIF -; † † Chisquare test.
